Celularity Inc., (CELU): Price and Financial Metrics

Celularity Inc., (CELU): $0.44

0.01 (+1.76%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

F

Add CELU to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#327 of 350

in industry

CELU Price/Volume Stats

Current price $0.44 52-week high $0.89
Prev. close $0.43 52-week low $0.16
Day low $0.43 Volume 147,763
Day high $0.47 Avg. volume 3,866,556
50-day MA $0.30 Dividend yield N/A
200-day MA $0.37 Market Cap 85.17M

CELU Stock Price Chart Interactive Chart >

CELU Stock Summary

  • CELU's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.19 -- higher than only 2.51% of US-listed equities with positive expected earnings growth.
  • In terms of twelve month growth in earnings before interest and taxes, CELULARITY INC is reporting a growth rate of -350.36%; that's higher than merely 3.7% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CELU comes in at -120.75% -- higher than that of just 3.7% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to CELULARITY INC, a group of peers worth examining would be DM, RIOT, STRC, SSRM, and OUST.
  • To dig deeper into the stock's financial statements, go to CELU's page on browse-edgar?action=getcompany&CIK=0001752828.

CELU Valuation Summary

  • In comparison to the median Healthcare stock, CELU's price/sales ratio is 40.91% higher, now standing at 3.1.
  • Over the past 56 months, CELU's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for CELU.

Stock Date P/S P/B P/E EV/EBIT
CELU 2023-12-29 3.1 0.4 -0.6 -1.1
CELU 2023-12-28 2.4 0.3 -0.4 -1.0
CELU 2023-12-27 2.1 0.3 -0.4 -0.9
CELU 2023-12-26 2.1 0.3 -0.4 -0.9
CELU 2023-12-22 2.3 0.3 -0.4 -1.0
CELU 2023-12-21 2.3 0.3 -0.4 -1.0

CELU's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CELU has a Quality Grade of C, ranking ahead of 32.67% of graded US stocks.
  • CELU's asset turnover comes in at 0.058 -- ranking 311th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows CELU's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.058 0.622 -1.726
2021-03-31 0.053 0.635 -1.174
2021-03-31 0.053 0.635 -1.174
2020-12-31 0.049 0.655 -0.724
2020-12-31 0.000 NA -0.169
2020-12-31 0.000 NA -0.008

CELU Price Target

For more insight on analysts targets of CELU, see our CELU price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.00 Average Broker Recommendation 1.25 (Strong Buy)

Celularity Inc., (CELU) Company Bio


Celularity Inc., a clinical stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies. The company is developing unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR, and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious diseases, and degenerative diseases. It also develops and manufactures biomaterials derived from the postpartum placenta. The company was founded in 2016 and is based in Florham Park, New Jersey.


CELU Latest News Stream


Event/Time News Detail
Loading, please wait...

CELU Latest Social Stream


Loading social stream, please wait...

View Full CELU Social Stream

Latest CELU News From Around the Web

Below are the latest news stories about CELULARITY INC that investors may wish to consider to help them evaluate CELU as an investment opportunity.

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

FLORHAM PARK, N.J., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today that on November 21, 2023, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq’s continued listing requirements of the Company’s failure to timely file a Form 10-Q for th

Yahoo | November 24, 2023

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

SFDA Classification Establishes Clear Regulatory Pathway for Importation of Celularity’s Commercial Biomaterial Products into the Kingdom of Saudi Arabia FLORHAM PARK, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced that its Halal Certified biomaterial products have been classified by the Saudi Food and Drug Authority

Yahoo | October 18, 2023

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

Pharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and

Yahoo | September 7, 2023

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapyAgreement underscores Celularity's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc.

Yahoo | August 29, 2023

Celularity Inc. Announces $3 Million Registered Direct Offering

FLORHAM PARK, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined

Yahoo | July 27, 2023

Read More 'CELU' Stories Here

CELU Price Returns

1-mo 56.81%
3-mo 106.09%
6-mo 47.40%
1-year -30.99%
3-year -95.69%
5-year N/A
YTD 77.85%
2023 -80.82%
2022 -74.80%
2021 -53.45%
2020 10.55%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!